Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes will comply with the requirements of the protocol should be enrolled in the study.~* A male or female between, and including, 18 and 41 years old at the time of vaccination.~* Subjects who previously participated in the study NCT00707798 and received one of the two investigational GSK2189242A vaccine formulations during the primary study.~* Written informed consent obtained from the subject.~* Free of obvious health problems as established by medical history, clinical examination and clinical laboratory assessment before entering into the study.~* Female subjects of non-childbearing potential (defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause) may be enrolled in the study.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test on the day of vaccination, and~ * has agreed to continue adequate contraception during the entire treatment period and for 2 months after vaccination.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the vaccination, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.~* Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting 30 days prior to the vaccination and ending one month (minimum 30 days) after vaccination.~* Administration of any pneumococcal vaccine other than the study vaccine during the period between end of study NCT00707798 and study vaccination.~* Bacterial pneumonia within the period between end of study NCT00707798 and study vaccination.~* Invasive pneumococcal disease (IPD) within the period between end of study NCT00707798 and study vaccination.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection (no laboratory testing required).~* History of thrombocytopenia or bleeding disorder.~* Anaphylactic reaction following the previous administration of the vaccine or history of reactions or allergic disease likely to be exacerbated by any component of the vaccine.~* Current serious neurologic or mental disorders.~* Inflammatory processes such as known chronic active infections (e.g. Hepatitis B, C).~* All past or current malignancies (excluding non-melanic skin cancer) and lymphoproliferative disorders.~* Acute disease at the time of enrolment/vaccination.~* Fever at the time of vaccination. Fever is defined as temperature \>= 37.5°C on oral setting.~* Physical examination positive for acrocyanosis, jaundice, splenomegaly.~* Acute or chronic, clinically significant anaemia, pulmonary, cardiovascular, hematologic, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests, at the discretion of the investigator~* Administration of immunoglobulins and/or any blood products within the three months preceding vaccination or planned administration during the study period.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.~* History of chronic alcohol consumption and/or drug abuse.~* Other conditions that the principal investigator judges may interfere with study findings.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 41 Years
- Healthy Volunteers: t

Study Arms:
- Formulation 1 (Type: EXPERIMENTAL): None
- Formulation 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete